Evidence map›Paper›PMID 39415910›Full record

ArticleEJHaem2024

Bleeding management in type 3 von Willebrand disease with anti-von Willebrand factor inhibitor: A literature review and case report.

Aurélie Briane, Valérie Horvais, Marianne Sigaud, Marc Trossaërt, Nicolas Drillaud, Catherine Ternisien, Marc Fouassier, Antoine Babuty

Abstract read
In one paragraph

Article in EJHaem, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aurélie BrianeService de Médecine Interne Nantes Université, CHU Nantes Nantes France.
Valérie HorvaisUnité d'Investigation Clinique 17 Nantes Université, CHU Nantes Nantes France.ORCID https://orcid.org/0000-0002-2988-5952
Marianne SigaudCentre de Ressource et de Compétence - Maladies Hémorragiques Constitutionnelles Nantes Université, CHU Nantes Nantes France.
Marc TrossaërtCentre de Ressource et de Compétence - Maladies Hémorragiques Constitutionnelles Nantes Université, CHU Nantes Nantes France.ORCID https://orcid.org/0000-0003-4072-839X
Nicolas DrillaudCentre de Ressource et de Compétence - Maladies Hémorragiques Constitutionnelles Nantes Université, CHU Nantes Nantes France.ORCID https://orcid.org/0000-0002-6500-5190
Catherine TernisienCentre de Ressource et de Compétence - Maladies Hémorragiques Constitutionnelles Nantes Université, CHU Nantes Nantes France.
Marc FouassierCentre de Ressource et de Compétence - Maladies Hémorragiques Constitutionnelles Nantes Université, CHU Nantes Nantes France.ORCID https://orcid.org/0000-0002-0964-0739
Antoine BabutyCentre de Ressource et de Compétence - Maladies Hémorragiques Constitutionnelles Nantes Université, CHU Nantes Nantes France.ORCID https://orcid.org/0000-0002-9284-7094

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of type 3 von Willebrand disease by infusion of von Willebrand factor (VWF) and factor VIII (FVIII) concentrates may lead to the development of anti-VWF antibodies, challenging haemostasis management. The systematic review of the literature presented here retrieved 15 such cases (surgery

Indexed as

allo‐antibodiesbleeding disordersemicizumabhaemostasisvon Willebrand disease

Identifiers

PMID39415910
PMCPMC11474279

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.